Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 15;12(6):1575. doi: 10.3390/cancers12061575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Pharmacokinetic/Pharmacodynamic correlation of ABN401. Quantitative analysis of ABN401 in plasma and tumor tissues in (A) EBC-1 and (B) SNU-5 models. Based on the tumor to plasma ratio of the AUC_inf value for ABN401 (AUC_tumor/AUC_plasma), K_p,ss values at a dose of 10 and 30 mg/kg of ABN401 were estimated. The dose and duration of ABN401 treatment required to inhibit c-MET phosphorylation were determined by immunohistochemistry (IHC) and Western blotting (WB) in (C) EBC-1 and (D) SNU-5 models. For analysis of the concentration–time relationship of PK/PD, data were integrated.

Pharmacokinetic/Pharmacodynamic correlation of ABN401. Quantitative analysis of ABN401 in plasma and tumor tissues in (A) EBC-1 and (B) SNU-5 models. Based on the tumor to plasma ratio of the AUC_inf value for ABN401 (AUC_tumor/AUC_plasma), K_p,ss values at a dose of 10 and 30 mg/kg of ABN401 were estimated. The dose and duration of ABN401 treatment required to inhibit c-MET phosphorylation were determined by immunohistochemistry (IHC) and Western blotting (WB) in (C) EBC-1 and (D) SNU-5 models. For analysis of the concentration–time relationship of PK/PD, data were integrated.